Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 494-499

  Chintoh, Araba F ^a,b   Mann, Steve W ^a,b   Lam, Loretta ^c   Lam, Carol ^c   Cohn, Tony A ^c   Fletcher, Paul J ^b   Nobrega, Jose N ^b   Giacca, Adria ^a,c   Remington, Gary ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; C PEPTIDE; GLUCOSE; INSULIN; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE CLAMP TECHNIQUE; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STEADY STATE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; METABOLISM; SECRETION; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; C-PEPTIDE; DISEASE MODELS, ANIMAL; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 58149109332     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318184b4c5     Document Type: Article

References (27)

1. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.
2. Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2006;21:369-372.
3. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl). 2003;170:157-166.
4. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-345.
5. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled double-blind multicentre comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2005;161:1837-1847.
6. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28.
7. Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother. 2001;35(12):1556-1558.
8. Rigalleau V Gatta B, Bonnaud S, et al. Diabetes as a result of atypical anti-psychotic drugs-a report of three cases. Diabet Med. 2000;17: 484-486.
9. Masand PS, Culpepper L, Henderson D, et al. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr. 2005;10 (suppl 14):1-15.
10. Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr. 2001;138:936-938.
11. Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand. 2002;105:235-236.
12. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156:1686-1696.
13. Kapur S, VanderSpek SC, Brownlee BA, et al. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther. 2003;305:625-631.
14. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
15. Stetten D, Welt ID, Ingle DJ, et al. Rates of glucose production and oxidation in normal and diabetic rats. J Biol Chem. 1951;192:817-830.
16. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes. 1987;36:914-924.
17. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289-297.
18. Patil BM, Kulkami NM, Unger BS. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur J Pharmacol. 2006;551:112-115.
19. Melkersson K. Clozapine and olanzapine, but not conventional anti- psychotics, increase insulin release in vitro. Eur Neuropsychopharmacol. 2004;4:115-119.
20. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862-871.
21. Melkersson K, Jansson E. Effect of the atypical antipsychotic clozapine on insulin release in vitro. Neuro Endocrinol Lett. 2007;28:854-860.
22. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68(suppl 1):20-27.
23. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. Clin Cornerstone. 2007;8(suppl 7):S30-S42.
24. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753-760.
25. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000; 26:903-912.
26. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry. 2004;(suppl 47):S76-S79.
27. Cohn T, Remington G, Zipursky RB, et al. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006;51:382-386.